Vasculitis & polymyalgia rheumatica
Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database
Study context
- Population
- Patients with large-vessel vasculitis (LVV) (TAK and giant cell arteritis (GCA)) in a Japanese administrative claims database, April 2008 to July 2023
- Participants
- 1,856 vs 2,149
- Comparison
- Serious infections (SI) cases vs matched controls, within TAK and GCA cohorts
- TAKn = 1,856
- GCAn = 2,149
- Outcome
- Risk factors of serious infections (SI; infection-related hospitalization)
Methodological detailsretrospective, administrative claims database, up to 5 controls per case matched on sex, age, days of follow-up and calendar year, conditional logistic regression
- Retrospective
- Administrative claims database
- Up to 5 controls per case matched on sex, age, days of follow-up and calendar year
- Conditional logistic regression
Main finding
As reported in the abstract
Risk factors of SI (aOR)
Observational data: associations, not effects.
Further findings
- Respiratory tract was the most frequent site of infection
Original publication
Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database. Arthritis Res Ther. Published 28 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →